These findings collectively underscore the pivotal role of surface NCL targeting and the detection of autoantibodies against its central RBD domain in distinguishing lung cancer patients, especially in the early stages, from healthy individuals (Figure 2). Here, NUCLEOLIN is linked to lung cancer.